Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3347767 | Diagnostic Microbiology and Infectious Disease | 2009 | 7 Pages |
Abstract
Tigecycline exposure (area under the concentration-time curve [AUC(0-â)] and maximum serum concentration [Cmax]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after 12.5- to 300-mg single doses. Nausea was more frequent in females (46%, 10/22) compared with males (31%, 11/36) after 100-mg doses. Most nausea (vomiting) events occurred â¤4 h (<6 h) after tigecycline. For doses â¤100 mg, the median duration of nausea and vomiting was approximately 5 h. Based on logistic regression, increased exposure (AUC(0-â) > Cmax) to tigecycline results in an increased rate of nausea (P ⤠.0001; = .0022) and vomiting (P ⤠.0001; = .0006). At the median AUC(0-â) (Cmax) for the 50-mg dose group, the probability of nausea and vomiting was 0.26 (0.29) and 0.07 (0.11), respectively. Model-predicted rates of nausea and vomiting were comparable with those observed for the tetracycline class of antibiotics, with tolerable rates predicted after 50-mg doses of tigecycline.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Julie Passarell, Elizabeth Ludwig, Kathryn Liolios, Alison K. Meagher, Thaddeus H. Grasela, Timothy Babinchak, Evelyn J. Ellis-Grosse,